New study finds certain genetic alterations in gallbladder cancer tumors correlate with poorer survival rates. Experts hope this research will lead to more personalized treatment approaches.
A recent analysis by researchers at Boston University School of Medicine has shed light on the impact of specific gene changes within gallbladder cancer tumors, revealing that these alterations are linked to shorter patient survival times. The study, published in the journal Cancers, analyzed real-world medical records from a large international database called TriNetX.
The research team identified more than 40,000 patients with gallbladder cancer and categorized them into two groups based on whether they had documented actionable gene changes (AGAs) within their tumors. They then matched the two groups for similar characteristics such as age, sex, race/ethnicity, cancer stage, surgery status, and chemotherapy use.
After comparing survival rates between the groups, the researchers found that patients with AGAs associated with genes like KRAS, ERBB2/HER2, PIK3CA, IDH1, FGFR1, TP53, or ARID1A had significantly lower overall survival compared to those without these gene changes. Eduardo Vega, MD, assistant professor of surgery at Boston University and corresponding author of the study, emphasized that genetic alterations within cancer cells could explain why some gallbladder patients fare worse despite receiving similar treatments.
"This research highlights the importance of considering tumor biology in treatment decisions for gallbladder cancer," Vega stated. "Ultimately, we aim to use genomic testing to identify higher-risk patients earlier and expand access to targeted therapies."
The study also uncovered important disparities between those who received genomic testing and had documented results versus those without such information. For instance, 51.0% of patients in the group without a documented actionable genomic alteration had an unknown race recorded, compared to only 3.7% in the group with documented genetic alterations. Additionally, white patients were more likely to have their genomic data available.
Vega improving access to genomic testing is crucial for advancing personalized cancer care. "We need to ensure that all patients, regardless of background or socioeconomic status, can benefit from these advanced diagnostic tools," he added.
The findings suggest a potential shift towards more tailored treatment approaches in gallbladder cancer management. By accounting for genetic variations within tumors, clinicians may be able to better predict patient outcomes and tailor therapies accordingly.
However, Vega emphasized the need for equitable access to genomic testing across different populations. "Precision medicine holds great promise but must also address systemic barriers that prevent some patients from benefiting fully," he concluded.
This study underscores the ongoing importance of molecular research in understanding and treating gallbladder cancer. As more data becomes available, it is hoped that these insights will lead to improved survival rates and better outcomes for affected individuals.
